Research programme: antibacterials - Johnson & Johnson

Drug Profile

Research programme: antibacterials - Johnson & Johnson

Alternative Names: ARQ 259034; C6-carbamate ketolides research programme - Johnson & Johnson; DQ-1; JNJ 10275798; JNJ 10278385; JNJ 17069546; JNJ 6333314; JNJ-Q1; MurF inhibitors - Johnson & Johnson; RWJ 670963

Latest Information Update: 13 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Fluoroquinolones; Ketolides; Small molecules
  • Mechanism of Action Cell wall inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; MurF synthetase inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 31 May 2010 Antimicrobial data from an in vitro study in Bacterial infections released by Johnson & Johnson Pharmaceutical Research & Development
  • 31 May 2010 Preclinical development is ongoing in USA
  • 02 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Bacterial Infections antimicrobial activity section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top